Abstract:A healthy host-microbiome relationship, crucial for intestinal homeostasis, is established early in postnatal life. Imbalance in the neonatal microbiome may lead to the development of chronic pathological conditions later in life. Dysbiosis of the gut microbiota is increasingly being linked to the etiology of both intestinal and systemic illnesses such as irritable bowel disease (IBD), cardiovascular diseases and diabetes, as well as kidney and neurological disorders. Gut dysbiosis also leads to the development of colorectal cancer (CRC). Despite substantial research, little is known about the interactions between microorganisms, their hosts, and their environments, or whether dysbiosis is a cause or consequence of disease. According to a recent hypothesis, bacterial species living in the mucus layer of the colon may determine whether cellular homeostasis is retained or inflammatory processes are elicited, either through direct interaction with intestinal epithelium or indirectly via bacterial metabolites. Recently, high throughput deep-sequencing technology has enabled the characterization of the microbiota in patients suffering from intestinal or extra-intestinal disorders, and a strong association between dysbiosis and disease development was found. However, specific disease drivers still need to be identified in most cases. Small compounds and metabolites produced by gut bacterial flora act as signaling molecules, such as neurotransmitters and neuropeptides that can profoundly influence host physiology. These metabolites play a crucial role in modulating gut-brain crosstalk. There is growing evidence that neurological disorders such as Alzheimer's disease, Parkinson’s and others, may originate or be exaggerated in response to microbial dysbiosis either directly or indirectly interfering with the drugs through metabolites. The present evidence on the role of the gut microbiota in disease development and drug metabolism is summarized in this review. Based on available studies, we can explore the potential of gut flora to alleviate disease progression.

Molecular basis of phytochemical-gut microbiota interactions

Synergistic Two-Way Interactions of Dietary Polyphenols and Dietary Components on the Gut Microbial Composition: Is There a Positive, Negative, or Neutralizing Effect in the Prevention and Management of Metabolic Diseases?

Metabolite interactions between host and microbiota during health and disease: Which feeds the other?

The Role of Gut Microbiota Associated Metabolites in Digestive Disorders

Gut Microbiota and Metabolic Syndrome: Relationships and Opportunities for New Therapeutic Strategies

Gut Microbiota, Dietary Phytochemicals, and Benefits to Human Health

Interactions between Gut Microbiota and Natural Bioactive Polysaccharides in Metabolic Diseases: Review

Phytochemicals That Influence Gut Microbiota as Prophylactics and for the Treatment of Obesity and Inflammatory Diseases

Gut microbiota-derived metabolites: implications for metabolic syndrome and therapeutic interventions

Therapeutic modulation of microbiota-host metabolic interactions.

Diet-gut microbiota-epigenetics in metabolic diseases: From mechanisms to therapeutics

Gut Microbiota-Derived Metabolites in the Development of Diseases

Advances in Gut Microbiota-Targeted Therapeutics for Metabolic Syndrome

Dysbiosis: Gut feeling

Microbial metabolites as modulators of host physiology

Short-chain fatty acid receptors and gut microbiota as therapeutic targets in metabolic, immune, and neurological diseases

Diet-induced metabolic changes of the human gut microbiome: importance of short-chain fatty acids, methylamines and indoles

Gut microbes in metabolic disturbances. Promising role for therapeutic manipulations?

Gut Microbiota Modulation as a Novel Therapeutic Strategy in Cardiometabolic Diseases

Emerging Paradigms in Inflammatory Disease Management: Exploring Bioactive Compounds and the Gut Microbiota

Messengers From the Gut: Gut Microbiota-Derived Metabolites on Host Regulation